1. Market Research
  2. > Healthcare
  3. > Pathology Market Trends
  4. > Drugs and Diagnostics for Hematological Disorders: Global Markets

Use this report to:
- Receive detailed information regarding screening, testing and treatment options for hematological disorders and blood cancer.
- Learn about the types of diagnostic and treatment strategies for the clinical management of hematological disorders and blood cancers.
- Gain insight into tests currently being used for hematological disorders and cancer diagnosis and prognosis, new developments, spending trends and revenue prospects for these technologies.

Highlights
- The global market for hematology drugs and diagnostics is expected to grow from nearly $86.5 billion in 2015 to $124.3 billion in 2020 at a compound annual growth rate of 7.5% from 2015-2020.
- The hematological cancers segment for this market is expected to grow from nearly $24.0 billion in 2015 to $38.2 billion in 2020 at a CAGR of 9.7% for the period 2015-2020.
- The hematological disorders segment of this market over the next five years will grow from nearly $57.3 billion in 2015 to $80.0 billion in 2020 at a CAGR of 6.9% for the period 2015-2020.

Introduction & Scope

INTRODUCTION

STUDY GOALS AND OBJECTIVES
This report, Hematological Disorders: Drug Technologies, Diagnostics and Global Markets (PHM116B), provides an overview of the current and potential global market for hematological disorders, treatments and testing technologies. The key objective is to present a comprehensive analysis of the current state of hematological disorders and blood cancers, therapy and technology, and utilization of the various therapeutic and diagnostic modalities to prevent and treat these disorders. The report's focus is on hematological disorder treatment strategies such as hematological therapeutics and drugs, chemotherapy, radiotherapy and immunotherapy, and other treatment modalities and testing and screening methods. The report also includes an overview of hematological disorders and staging, diagnostic tests and technologies. Important trends in the field of hematological disorders and cancer research, new developments, and sales forecasts by treatment and screening categories from 2015 through 2020 are provided in this report. Issues and trends addressed in this report are based on information from industry sources, regulatory and healthcare policies, demographics and other factors that directly affect the hematological disorders and blood cancer market.

REASONS FOR DOING THIS STUDY
This study was conducted to provide detailed information regarding screening, testing and treatment options for hematological disorders and blood cancer. There is an increasing need for new and innovative technologies. This industry is experiencing tremendous growth. Many diseases discussed in this report are global issues, and a need exists for newer diagnostic and treatment strategies. Some of these conditions affect children and the elderly. This study looks at most types of diagnostic and treatment strategies for the clinical management of hematological disorders and blood cancers. This BCC market research report will increase the awareness of current and emerging drugs and technologies for hematological disorders and blood cancers, including hematological disorder therapeutics, chemotherapy, radiation therapy, surgical therapy, immunotherapy and nutrition therapy.

INTENDED AUDIENCE
This report is an exhaustive study on the global hematological disorders and blood cancer market, with important statistics and analysis on existing drugs and diagnostic technologies, latest trends, market structure, market size, key drug segments and trends in technology. This study contributes to the areas of market growth in hematological disorders and blood cancer prevention and treatment strategies from the point of view of manufacturers, product suppliers, healthcare providers and consumers of hematological disorder and cancer products and services. This study will be of interest largely to the pharmaceutical and biotechnology industries, as well as clinics, hospitals and research institutes. This report may also prove crucial for investment firms in the concerned sector. This report shows tests currently being used for hematological disorders and cancer diagnosis and prognosis, new developments, spending trends and revenue prospects for these technologies. The report provides market data for 2012 to 2020 and also covers commercial prospects for hematological disorders and cancer diagnostic assays, current tests in use and their future.

SCOPE OF THE STUDY
The scope of this study covers instruments, reagents, testing, screening technology and the therapeutics markets for hematological disorders, including hemophilia and blood cancers. The report also discusses the regulatory environment, current technologies, new technologies, hematological disorders and cancer incidence, market projections and market share, along with latest trends, and clinical and new developments.

METHODOLOGY
Both primary and secondary research methodologies were used in preparing this report. Secondary sources include books, newspapers, trade journals, white papers, industry portals, government agencies, trade associations, industry news and developments, and paid and free databases. The base year of the report is 2015, with forecast data provided through 2020. Historical, base year and forecast data are
provided for each market segment of this report. The report provides a comprehensive review of hematological disorders, incidence and development of these disorders, drugs currently being used and diagnostic technologies. The report also reviews technological developments, product innovations/introductions and recent strategic industry activity of major players across various product categories. Growth rates, global incidence and projections are determined through a compilation of data, including past trends, future trends, demographics, incidence, mortality, products in R&D and current product growth. Forecasts and projections are based on estimates such as the current trends, potential users, mergers and acquisitions, and market trends.

A comprehensive and exhaustive search of the literature on hematological disorders and blood cancers, assay development and already-marketed products, global incidence and latest drug developments was conducted. These secondary sources included scientific journals and articles, textbooks, press releases, marketing literature, other product/promotional literature, annual reports, security analyst reports and other publications. A patent search and analysis were also conducted. Some informal interviews were also conducted with experts and personnel in this area at biotech and pharmaceutical companies. Other resources included academics, technology and consulting companies.

INFORMATION SOURCES
Many companies within the industry were surveyed to obtain data for this study. Included were manufacturers and end users of products, such as the pharmaceutical and biotechnical industries and research institutes. Data were gathered from various industry sources. BCC Research spoke with officials within the industry and consulted newsletters, company literature, product literature and a host of technical articles, journals, indexes and abstracts. Exhaustive investigations of databases by key terminology were completed. In addition, data were compiled from current financial, trade and government sources.

Table Of Contents

Drugs and Diagnostics for Hematological Disorders: Global Markets
CHAPTER 1 INTRODUCTION 2
STUDY GOALS AND OBJECTIVES 2
REASONS FOR DOING THIS STUDY 2
INTENDED AUDIENCE 2
SCOPE OF THE STUDY 3
METHODOLOGY 3
INFORMATION SOURCES 3
ANALYST'S CREDENTIALS 4
RELATED BCC RESEARCH REPORTS 4
ABOUT BCC RESEARCH 4
CONDITIONS OF PURCHASE 4
ADDITIONAL COPIES 5
CUSTOM ANALYSES 5
BCC RESEARCH WEBSITE 5
DISCLAIMER 5
CHAPTER 2 SUMMARY 7
SUMMARY TABLE GLOBAL MARKET FOR HEMATOLOGY DRUGS AND DIAGNOSTICS,
BY SEGMENT, THROUGH 2020 ($ MILLIONS) 8
SUMMARY FIGURE GLOBAL MARKET FOR HEMATOLOGY DRUGS AND DIAGNOSTICS,
BY SEGMENT, 2012-2020 ($ MILLIONS) 9
CHAPTER 3 HEMATALOGICAL DISORDERS 11
TABLE 1 KEY BLOOD DISORDERS 11
TABLE 2 MALIGNANT BLOOD DISORDERS 11
TABLE 3 NONMALIGNANT BLOOD DISORDERS 12
BLOOD 13
TABLE 4 TYPE OF BLOOD CELLS AND FUNCTIONS 13
TABLE 5 COMPONENTS OF BLOOD 14
BLOOD DISORDERS/DISEASES 14
ANEMIA 14
Types of Anemia 14
TABLE 6 THREE MAJOR TYPES OF ANEMIA 15
TABLE 7 CAUSES OF ANEMIA 15
Symptoms 16
TABLE 8 SYMPTOMS OF ANEMIA 16
TABLE 9 ANEMIA: TYPES, CAUSES AND TREATMENT 17
MEGALOBLASTIC ANEMIAS 18
Cobalamin Deficiency 18
TABLE 10 DRUGS THAT CAN CAUSE COBALAMIN DEFICIENCY BY CLASS 19
Folate Deficiency 19
TABLE 11 DRUGS THAT CAN CAUSE FOLATE DEFICIENCY 20
Diagnostic Tests 20
Schilling Test 20
Serum Ferritin and Iron Studies 21
Other Tests 21
Treatment 21
HEMOGLOBIN DISORDERS 22
Categories 22
Thalassemia 22
Sickle Cell Anemia 22
TABLE 12 SICKLE CELL ANEMIA: KEY FACTS 23
Causes 23
World Health Organization's Resolutions 24
HEMOLYTIC ANEMIA 24
TABLE 13 LAB TESTS FOR ANEMIA 24
Treatment 25
Anemia Medications 25
PRIMARY THROMBOCYTHEMIA 26
Hemostasis: Steps of Mechanism 26
TABLE 14 HEMOSTASIS: THREE MAJOR STEPS 27
Types of Hemostasis 27
Hemostasis in Emergency Medicine 27
Artificial Hemostasis 28
TABLE 15 DRUGS THAT AFFECT THE ACTIVITY OF PLATELETS 29
TABLE 16 ANTICOAGULANTS THAT ACT ON THROMBIN 29
BLEEDING DISORDERS 30
TABLE 17 BLEEDING DISORDERS 30
TABLE 18 SYMPTOMS OF BLEEDING DISORDERS 31
TABLE 19 SIGNS AND TESTS FOR BLEEDING DISORDERS 31
Hemophilia 31
TABLE 20 KEY CHARACTERISTICS OF HEMOPHILIA 32
Classification 32
Historical Background 33
The Clotting Cascade 33
Hemorrhage 34
Natural Inhibitors 34
Acquired Hemophilia 35
Hemophilia Types 35
Symptoms and Complications 35
Diagnosis 36
Hemophilia and Bleeding 36
Genetic Testing 37
Treatment 37
TABLE 21 FVIII INHIBITORS 40
TABLE 22 MEDICATIONS FOR TREATING HEMOPHILIA 41
Factor VIII Products 41
TABLE 23 FACTOR VIII PRODUCTS 42
Antifibrinolytics 42
TABLE 24 ANTIFIBRINOLYTICS BY DRUG 42
Antihemophilic Agents 42
TABLE 25 ANTIHEMOPHILIC AGENTS BY CLASS 43
Coagulation Factor VIIa, Recombinants 43
Factor VIIa, Recombinant (NovoSeven) 43
Monoclonal Antibodies 43
Rituximab (Rituxan) 44
von Willebrand Disease 44
Symptoms and Diagnosis 44
Treatment 44
THROMBOPHILIA 45
Diagnosis and Treatment 45
THROMBOSIS 46
TABLE 26 FORMATION OF THROMBUS 47
Superficial Thrombophlebitis 47
DEEP VENOUS THROMBOSIS 47
Tests 47
Treatment 48
Surgery 49
HEREDITARY HEMORRHAGIC TELANGIECTASIA 49
ERYTHROCYTOSIS 50
Absolute Polycythemia 50
Types 50
Primary Polycythemia 50
Secondary Polycythemia 50
Chuvash Polycythemia 51
Relative Polycythemia 51
WHITE BLOOD CELL DISORDERS 52
Treatment 52
NEUTROPENIA 53
Causes 53
TABLE 27 CAUSES OF NEUTROPENIA 53
Symptoms and Diagnosis 54
Treatment 54
NEUTROPHILIA 55
BLOOD DISORDERS AFFECTING PLATELETS 55
TABLE 28 WHITE BLOOD CELL DISORDERS 55
Thrombocytopenia 56
Treatment 56
Lymphocytopenia 56
Treatment 57
Lymphocytic Leukocytosis 57
Monocytosis 57
Thrombocythemia and Thrombocytosis 58
Types 58
Primary Thrombocythemia 58
Secondary Thrombocytosis 58
TABLE 29 CAUSES OF SECONDARY THROMBOCYTOSIS 59
Symptoms 59
TABLE 30 DIAGNOSTIC TESTS FOR THROMBOCYTHEMIA 60
Treatment 60
TABLE 31 MEDICINES FOR THROMBOCYTHEMIA 61
Thrombocytopenia 61
Causes 61
TABLE 32 CAUSES OF THROMBOCYTOPENIA 62
RARE CONDITIONS THAT CAUSE BLOOD CLOTS 63
Signs and Symptoms 63
TABLE 33 SIGNS OF EXTERNAL BLEEDING 63
Tests 63
Treatment 64
SEVERE THROMBOCYTOPENIA 64
EOSINOPHILS AND DISORDERS 64
TABLE 34 COMMON DRUGS TO TREAT EOSINOPHILIA 65
BASOPHILIC DISORDERS 65
PLASMA CELL DISORDERS 65
CHAPTER 4 HEMATOLOGICAL CANCERS 68
TABLE 35 HEMATOLOGICAL CANCERS (BLOOD CANCERS) 68
CLASSIC CLASSIFICATION 69
TABLE 36 RELATIVE OCCURRENCE OF HEMATOLOGICAL MALIGNANCIES IN THE
U.S., 2016 (NUMBER/%) 69
TABLE 37 TYPES OF HEMATOLOGICAL CANCERS 70
ACUTE MYELOID LEUKEMIA 71
CHRONIC MYELOID LEUKEMIA 71
ACUTE LYMPHOCYTIC LEUKEMIA 72
CHRONIC LYMPHOCYTIC LEUKEMIA 72
HODGKIN LYMPHOMA 72
NON-HODGKIN LYMPHOMA 73
Treatment and Side Effects 73
MULTIPLE MYELOMA 73
MYELODYSPLASTIC SYNDROME 74
Diagnosis 74
TABLE 38 FDA APPROVALS OF DRUGS FOR HEMATOLOGICAL
DISORDERS/DISEASES, 2014-2016 74
TABLE 39 FDA APPROVALS OF DRUGS FOR HEMATOLOGICAL
DISORDERS/DISEASES, 2012 77
TABLE 40 FDA APPROVALS OF DRUGS FOR HEMATOLOGICAL
DISORDERS/DISEASES, 2011 78
TABLE 41 FDA APPROVALS OF DRUGS FOR HEMATOLOGICAL
DISORDERS/DISEASES, 1996-2010 79
CHAPTER 5 LEUKEMIA 83
LYMPHOCYTIC LEUKEMIAS 84
MYELOGENOUS LEUKEMIAS 84
TABLE 42 TYPES OF LEUKEMIA 84
TABLE 43 TYPES OF LEUKEMIA AND KEY FEATURES 85
SYMPTOMS 86
CAUSES 87
DIAGNOSIS 88
TESTS 88
TABLE 44 DIAGNOSTIC EXAMS FOR LEUKEMIA 89
Complete Blood Count 89
White Cell Differential 89
Blood Smear 89
TABLE 45 ADDITIONAL TESTS 89
Fluorescence In Situ Hybridization (FISH) 90
Flow Cytometry 90
Immunophenotyping 90
Karyotype Test 91
Polymerase Chain Reaction 91
Bone Marrow Aspiration/Biopsy 91
Spinal Tap (Lumbar Puncture) and Cerebrospinal Fluid (CSF) Analysis 91
Immunophenotyping or Phenotyping by Flow Cytometry 91
Cytogenetics and Fluorescent In Situ Hybridization 92
Polymerase Chain Reaction (PCR) 92
TABLE 46 PCR TESTS 92
Non-Laboratory Tests 92
TABLE 47 NON-LABORATORY TESTS 92
TREATMENT 93
TABLE 48 COMMON TREATMENTS USED TO FIGHT LEUKEMIA 93
TABLE 49 NEWER CLASSES OF DRUGS 94
Drug Therapies for Blood Cancers 94
TABLE 50 ACUTE LYMPHOBLASTIC LEUKEMIA TREATMENT 96
TABLE 51 DRUGS APPROVED FOR ACUTE LYMPHOBLASTIC LEUKEMIA 97
TABLE 52 DRUGS APPROVED FOR CHRONIC LYMPHOCYTIC LEUKEMIA 98
TABLE 53 DRUGS APPROVED FOR ACUTE MYELOID LEUKEMIA 99
TABLE 54 DRUGS APPROVED FOR CHRONIC MYELOGENOUS LEUKEMIA 100
Hairy Cell Leukemia: Treatment 100
T-CELL PROLYMPHOCYTIC LEUKEMIA 101
TABLE 55 T-CELL PROLYMPHOCYTIC LEUKEMIA: TREATMENT PLAN 101
JUVENILE MYELOMONOCYTIC LEUKEMIA 101
STAGES OF LEUKEMIA 102
TABLE 56 FACTORS AFFECTING LEUKEMIA STAGING AND PROGNOSIS 102
TREATMENTS AND DRUGS 102
Stem Cell Transplantation 102
Allogeneic Stem Cell Transplant 102
Autologous Stem Cell Transplant 103
Chemotherapy 103
Types of Chemotherapy for Leukemia 103
Chemotherapy for Acute Leukemias 103
Chemotherapy for Chronic Leukemias 104
TABLE 57 CHEMOTHERAPY DRUGS FOR CML 104
TABLE 58 CHEMOTHERAPY DRUGS FOR CLL 104
Intrathecal Chemotherapy 104
Targeted Drug Therapy for Leukemia 104
TABLE 59 TARGETED THERAPY DRUGS 105
Monoclonal Antibody Therapy 105
Radioimmunotherapy 105
TABLE 60 ADVANTAGES OF RADIOIMMUNOTHERAPY 106
Radiation Therapy 106
TABLE 61 COMMON RADIATION TREATMENTS: LEUKEMIA 106
External Beam Radiation Therapy 107
Total Body Irradiation 107
Total Marrow Irradiation 107
Nutrition Therapy after a Stem Cell Transplant 107
Managing Side Effects with Naturopathic Therapies 108
Pain Management for Leukemia 108
TABLE 62 PAIN MEDICATIONS 108
TABLE 63 EMERGING THERAPIES FOR LEUKEMIA 108
CONCLUSIONS 109
CHAPTER 6 LYMPHOMA 111
OVERVIEW 111
LYMPHOMA CAUSES 112
TABLE 64 CAUSES OF LYMPHOMA 113
CLASSIFICATION 113
TABLE 65 LYMPHOMA TYPES 114
STAGING 115
TABLE 66 STAGING FOR HL AND NHL TUMORS 116
NON-HODGKIN LYMPHOMA 116
TABLE 67 MATURE B-CELL NEOPLASMS 117
TABLE 68 MATURE T-CELL AND NATURAL KILLER CELL NEOPLASMS 117
TABLE 69 HODGKIN LYMPHOMA 118
TABLE 70 IMMUNODEFICIENCY-ASSOCIATED LYMPHOPROLIFERATIVE DISORDERS 118
SIGNS AND SYMPTOMS 118
TABLE 71 SYMPTOMS OF NON-HODGKIN LYMPHOMA 119
TABLE 72 FIVE-YEAR RELATIVE SURVIVAL BY STAGE AT DIAGNOSIS: NON HODGKIN
LYMPHOMA, 2006-2012 (%) 119
DIAGNOSIS AND TESTS 120
Biopsy 120
Imaging Studies 120
TABLE 73 IMAGING TESTS FOR LYMPHOMA 120
Bone Marrow Examination 121
Other Tests 121
Lumbar Puncture 121
Organ Function Tests 121
PROGNOSTIC FACTORS 121
TABLE 74 THE INTERNATIONAL PROGNOSTIC INDEX FOR HL 121
TABLE 75 THE INTERNATIONAL PROGNOSTIC INDEX FOR NHL 122
LYMPHOMA TREATMENT 122
RADIATION AND CHEMOTHERAPY 123
RADIATION THERAPY 123
CHEMOTHERAPY 123
BIOLOGICAL THERAPY 124
TABLE 76 PROMISING THERAPIES FOR TREATING LYMPHOMA 124
COMPLEMENTARY/ALTERNATIVE THERAPIES 124
CHAPTER 7 MULTIPLE MYELOMA 127
OVERVIEW 127
CAUSE 128
SYMPTOMS 128
COMPLICATIONS OF MYELOMA 129
Cryoglobulinemia 129
Amyloidosis 129
TYPES OF MYELOMA 129
INCIDENCE 130
DIAGNOSIS 130
TESTS 131
Prognostic Indicators 132
TABLE 77 PROGNOSTIC INDICATORS FOR MYELOMA 132
Bone Marrow Examination 132
TABLE 78 OTHER BONE MARROW TESTS 132
STAGING 133
Monoclonal Gammopathy of Undetermined Significance 133
Smoldering Multiple Myeloma 134
Indolent Multiple Myeloma 134
Symptomatic Multiple Myeloma 134
TABLE 79 MYELOMA: STAGING CRITERIA 134
TREATMENT AND PROGNOSIS 135
TABLE 80 MYELOMA'S RESPONSE TO TREATMENT 135
Myeloma Therapy 136
Chemotherapy 136
Radiation Therapy 136
Stem Cell Transplantation 137
Supportive Care 138
TABLE 81 SUPPORTIVE CARE FOR MYELOMA 138
OTHER DRUG THERAPIES 138
NEW DRUG THERAPIES 139
TABLE 82 DRUGS FOR MULTIPLE MYELOMA 140
TABLE 83 NEW AND EMERGING THERAPIES FOR MYELOMA 141
CONCLUSIONS 144
CHAPTER 8 MYELODYSPLASTIC SYNDROMES 147
TABLE 84 CHARACTERISTICS OF MDS 147
TABLE 85 CAUSES OF MDS 148
TABLE 86 MDS OR AML: THREE CATEGORIES 148
CLASSES OF MDS 149
TABLE 87 MYELODYSPLASTIC SYNDROMES: KEY FACTS 149
TABLE 88 FAB CLASSIFICATION OF MDS 150
TABLE 89 THE 2008 WHO CLASSIFICATION OF MDS 151
INTERNATIONAL PROGNOSTIC SCORING SYSTEM 151
TABLE 90 INTERNATIONAL PROGNOSTIC SCORING SYSTEM RISK GROUPS AND
PROGNOS (YEARS) 152
DIAGNOSIS AND TESTS 152
TABLE 91 CHANGES IN CELLS DUE TO MDS 153
PROGNOSIS AND TREATMENT OPTIONS 154
CHEMOTHERAPY 154
SUPPORTIVE CARE 154
DRUG PROFILES 156
EPOETIN ALFA (PROCRIT, EPOGEN) 156
DARBEPOETIN (ARANESP) 157
SARGRAMOSTIM (LEUKINE) 157
FILGRASTIM (NEUPOGEN) 157
DECITABINE (DACOGEN) 157
LENALIDOMIDE (REVLIMID) 157
VIDAZA (AZACITIDINE) 158
PREVIOUSLY TREATED MYELODYSPLASTIC SYNDROMES 158
CONCLUSIONS 158
CHAPTER 9 MYELOPROLIFERATIVE DISORDERS 162
TYPES OF CHRONIC MYELOPROLIFERATIVE DISORDERS 162
TABLE 92 CHRONIC MYELOPROLIFERATIVE DISORDERS 163
CLASSIFICATION: WHO 167
TABLE 93 CLASSIFICATION OF MYELOID NEOPLASMS ACCORDING TO THE 2008
WHO CLASSIFICATION SCHEME 167
TABLE 94 MYELOPROLIFERATIVE NEOPLASMS: KEY FACTS 169
STAGES OF CHRONIC MYELOPROLIFERATIVE DISORDERS 169
DIAGNOSIS 169
TESTS 169
TABLE 95 DIAGNOSTIC TESTS 170
TREATMENT 170
OTHER DRUG THERAPY 170
POLYCYTHEMIA VERA 170
OVERVIEW 171
TABLE 96 SYMPTOMS OF POLYCYTHEMIA VERA 171
CAUSES 172
RISK FACTORS 172
TABLE 97 BLOOD TESTS FOR POLYCYTHEMIA VERA 172
TREATMENT OF POLYCYTHEMIA VERA 172
Drugs for Treating Polycythemia Vera 173
TABLE 98 TREATMENT FOR POLYCYTHEMIA VERA 173
PROGNOSIS 173
COMPLICATIONS 174
Blood Clots 174
Enlarged Spleen (Splenomegaly) 174
Problems Due to High Levels of Red Blood Cells 174
OTHER BLOOD DISORDERS 174
CHRONIC IDIOPATHIC MYELOFIBROSIS 174
CAUSES 174
TABLE 99 CAUSATIVE FACTORS FOR MYELOFIBROSIS 175
TABLE 100 POTENTIAL COMPLICATIONS FROM MYELOFIBROSIS 175
PATHOGENESIS 176
DIAGNOSIS 176
TABLE 101 WHO DIAGNOSTIC CRITERIA FOR PMF 177
PROGNOSIS 177
TABLE 102 RISK FACTORS 178
SYMPTOMS 178
TABLE 103 IDIOPATHIC MYELOFIBROSIS AND SYMPTOMS 178
TABLE 104 PROGNOSIS FACTORS 179
TREATMENTS FOR MYELOFIBROSIS 179
TABLE 105 TREATMENT OF CHRONIC IDIOPATHIC MYELOFIBROSIS 181
Experimental Drug Therapy 181
Pomalidomide 182
TABLE 106 SOMATIC MUTATIONS 183
ESSENTIAL THROMBOCYTHEMIA 183
TABLE 107 CAUSES OF THROMBOCYTOSIS 184
SYMPTOMS 184
TABLE 108 SYMPTOMS OF ESSENTIAL THROMBOCYTOSIS 185
PATHOPHYSIOLOGY 185
DIAGNOSIS 185
TABLE 109 ESSENTIAL THROMBOCYTHEMIA: DIAGNOSTIC CRITERIA 186
TREATMENT 186
PROGNOSIS 186
CAUSES, INCIDENCE AND RISK FACTORS 187
GENES: ESSENTIAL THROMBOCYTHEMIA 187
TREATMENT OF ESSENTIAL THROMBOCYTHEMIA 187
Diagnosis 188
TABLE 110 TREATMENT OF ET 189
ANTI-PLATELET TREATMENT 189
ADP RECEPTOR ANTAGONISTS 190
PLATELET-LOWERING TREATMENT 190
Anagrelide 190
Interferon-a (IFN-a) 190
ALTERNATIVE CYTOREDUCTIVE THERAPY 191
Pipobroman (PI) 191
Busulfan (BU) 191
Prognosis 191
Implication of the Description of JAK2 V617F Mutation on the
Management of ET 192
CHRONIC NEUTROPHILIC LEUKEMIA 192
TREATMENT OF CHRONIC NEUTROPHILIC LEUKEMIA 192
TABLE 111 TREATMENT OF CHRONIC NEUTROPHILIC LEUKEMIA 192
CHRONIC EOSINOPHILIC LEUKEMIA 192
TABLE 112 SYMPTOMS OF CHRONIC EOSINOPHILIC LEUKEMIA 193
TREATMENT OF CHRONIC EOSINOPHILIC LEUKEMIA 193
TABLE 113 TREATMENT OF CHRONIC EOSINOPHILIC LEUKEMIA 193
PIPELINE DRUGS 193
Incyte 193
Jakavi in Europe 195
SUMMARY 195
TABLE 114 CURRENT DRUGS 196
CHAPTER 10 EPIDEMIOLOGY OF HEMATOLOGICAL CANCERS 198
TABLE 115 CANCER KEY FACTS 199
TABLE 116 INCREASE IN CANCER BURDEN: FACTORS 200
INDIA 201
KENYA 201
WORLDWIDE INCIDENCE OF BLOOD CANCERS 202
TABLE 117 GLOBAL INCIDENCE OF BLOOD CANCERS, 2012 (NO./%) 203
TABLE 118 GLOBAL INCIDENCE OF BLOOD CANCERS, 2012 (NO.) 203
TABLE 119 GLOBAL INCIDENCE OF BLOOD CANCERS IN MEN, 2012 (NO./%) 204
TABLE 120 GLOBAL INCIDENCE OF BLOOD CANCERS IN WOMEN, 2012 (NO./%) 204
TABLE 121 TOP 10 COUNTRIES' CANCER INCIDENCE RATES (PER 100,000
POPULATION) 205
BLOOD CANCER INCIDENCE IN THE UNITED STATES 205
TABLE 122 ESTIMATED INCIDENCE OF BLOOD CANCERS IN THE U.S., 2011 VS.
2016 (PER 100,000 POPULATION) 206
FIGURE 1 ESTIMATED INCIDENCE OF BLOOD CANCERS, IN THE U.S., 2011 VS. 2016
(PER 100,000 POPULATION) 207
TABLE 123 ESTIMATED NEW CASES OF LEUKEMIA, LYMPHOMA AND MYELOMA IN
THE U.S., 2016 (NO.) 208
FIGURE 2 ESTIMATED NEW CASES OF LEUKEMIA, LYMPHOMA AND MYELOMA IN
THE U.S., 2016 (NO.) 208
TABLE 124 ESTIMATED LEUKEMIA AND LYMPHOMA INCIDENCE AND DEATHS IN
THE U.S., 2016 (NO.) 209
FIGURE 3 ESTIMATED LEUKEMIA AND LYMPHOMA INCIDENCE AND DEATHS IN THE
U.S., 2016 (NO.) 209
DEATHS FROM BLOOD CANCERS 210
LEUKEMIA 210
NUCLEAR REACTORS AND BLOOD CANCERS 210
SIGNS AND SYMPTOMS 211
LEUKEMIA IN CHILDREN AND ADOLESCENTS 212
GLOBAL INCIDENCE 212
TABLE 125 GLOBAL INCIDENCE OF LEUKEMIA, 2012 (NUMBER/%) 213
LEUKEMIA IN THE UNITED STATES 213
TABLE 126 U.S. LEUKEMIA INCIDENCE STATISTICS, 2012 214
TABLE 127 ESTIMATED NEW CASES OF LEUKEMIA AND DEATHS IN THE U.S.,
2010-2016 (NO.) 214
FIGURE 4 ESTIMATED NEW CASES OF LEUKEMIA AND DEATHS IN THE U.S.,
2010-2016 (NO.) 215
TABLE 128 ESTIMATED NEW CASES OF LEUKEMIA IN ADULTS AND CHILDREN IN
THE U.S., 2016 215
TABLE 129 ESTIMATED PREVALENCE OF DIFFERENT TYPES OF LEUKEMIA IN THE
U.S., 2008 (NO.) 216
FIGURE 5 ESTIMATED PREVALENCE OF DIFFERENT TYPES OF LEUKEMIA IN THE
U.S., 2008 (NO.) 216
Leukemia in Children and Adolescents 216
TABLE 130 PREVALENCE OF LEUKEMIA IN THE U.S., 2016 (NO.) 217
FIGURE 6 PREVALENCE OF LEUKEMIA IN THE U.S., 2016 (NO.) 218
Adolescents and Young Adults 218
Adults 219
TABLE 131 TYPES OF LEUKEMIA IN ADULTS IN THE U.S. AND AGE GROUP 219
TABLE 132 ESTIMATED LEUKEMIA INCIDENCE AND DEATHS IN THE U.S. BY TYPE,
2012 (NO.) 219
FIGURE 7 ESTIMATED LEUKEMIA INCIDENCE AND DEATHS IN THE U.S. BY TYPE,
2012 (NO.) 220
TABLE 133 AGE-ADJUSTED INCIDENCE RATES OF LEUKEMIA IN THE U.S. BY RACE,
SEER 18, 2009-2013 (PER 100,000 POPULATION) 221
Survival 221
TABLE 134 FIVE-YEAR RELATIVE SURVIVAL RATES IN THE U.S. FOR LEUKEMIA,
2005-2011 (%) 221
TABLE 135 ESTIMATED DEATHS FROM LEUKEMIA IN THE U.S., 2016 (NO). 222
FIGURE 8 ESTIMATED DEATHS FROM LEUKEMIA IN THE U.S., 2016 (NO). 222
LEUKEMIA INCIDENCE IN THE UNITED KINGDOM 223
TABLE 136 NEW CASES OF LEUKEMIA IN THE U.K., 2013 (NO.) 223
Cause 226
WORLDWIDE MORTALITY RATES: LEUKEMIA 226
TABLE 137 GLOBAL ESTIMATES OF LEUKEMIA DEATHS/MORTALITY RATES, 2012 227
LYMPHOMA 228
SIGNS AND SYMPTOMS 229
POSSIBLE CAUSES 229
TREATMENT 230
WORLDWIDE INCIDENCE OF NHL 230
TABLE 138 GLOBAL ESTIMATED INCIDENCE RATES OF NON-HODGKIN LYMPHOMA
FOR ALL AGES AND BOTH SEXES, 2012 230
TABLE 139 GLOBAL ESTIMATED NON-HODGKIN LYMPHOMA MORTALITY RATES BY
ALL AGES AND BOTH SEXES, 2012 231
GLOBAL INCIDENCE OF HODGKIN'S LYMPHOMA 232
TABLE 140 GLOBAL ESTIMATED INCIDENCE OF HODGKIN LYMPHOMA FOR ALL
AGES AND BOTH SEXES, 2012 233
CANADA: LYMPHOMA 233
EUROPEAN UNION 234
Non-Hodgkin's Lymphoma 234
TABLE 141 ESTIMATED INCIDENCE OF NON-HODGKIN LYMPHOMA IN EU-27
COUNTRIES BY GENDER, 2008 (AGE-STANDARDIZED RATES PER 100,000
POPULATION)
234
FIGURE 9 ESTIMATED INCIDENCE OF NON-HODGKIN LYMPHOMA IN EU-27
COUNTRIES BY GENDER, 2008 (AGE-STANDARDIZED RATES PER 100,000
POPULATION)
235
TABLE 142 ESTIMATED NON-HODGKIN LYMPHOMA MORTALITY RATES IN EU-27
COUNTRIES BY GENDER, 2008 (AGE-STANDARDIZED RATES PER 100,000
POPULATION)
236
FIGURE 10 ESTIMATED NON-HODGKIN LYMPHOMA MORTALITY RATES IN EU-27
COUNTRIES BY GENDER, 2008 (AGE-STANDARDIZED RATES PER 100,000) 237
Hodgkin Lymphoma in EU: 2012 237
TABLE 143 ESTIMATED HODGKIN LYMPHOMA INCIDENCE AND MORTALITY RATES
IN EU-27 COUNTRIES, 2012 (ESTIMATED RATES PER 100,000 POPULATION) 238
FIGURE 11 ESTIMATED HODGKIN LYMPHOMA INCIDENCE AND MORTALITY RATES
IN EU-27 COUNTRIES, 2012 (ESTIMATED RATES PER 100,000 POPULATION) 239
LYMPHOMA IN THE UNITED STATES 240
New Cases 240
TABLE 144 ESTIMATED LYMPHOMA INCIDENCE AND DEATHS IN THE U.S., 2016
(NO.) 240
FIGURE 12 ESTIMATED LYMPHOMA INCIDENCE AND DEATHS IN THE U.S., 2016
(NO.) 241
TABLE 145 ESTIMATED LYMPHOMA INCIDENCE AND DEATHS IN THE U.S.,
2011-2012 (NO.) 242
FIGURE 13 ESTIMATED LYMPHOMA INCIDENCE AND DEATHS IN THE U.S.,
2011-2012 (NO.) 242
TABLE 146 ESTIMATED NEW CASES OF LYMPHOMA IN THE U.S. BY TYPE,
2011-2016 (NO.) 243
FIGURE 14 ESTIMATED NEW CASES OF LYMPHOMA IN THE U.S. BY TYPE,
2011-2016 (NO.) 243
TABLE 147 ESTIMATED NEW CASES OF LYMPHOMA IN THE U.S. BY TYPE AND
GENDER, 2012 (NO.) 244
FIGURE 15 ESTIMATED NEW CASES OF LYMPHOMA IN THE U.S. BY TYPE AND
GENDER, 2012 (NO.) 244
TABLE 148 ESTIMATED DEATHS FROM LYMPHOMA IN THE U.S. BY TYPE AND
GENDER, 2011 (NO.) 245
FIGURE 16 ESTIMATED DEATHS FROM LYMPHOMA IN THE U.S. BY TYPE AND
GENDER, 2011 (NO.) 245
TABLE 149 U.S. AGE-SPECIFIC NHL INCIDENCE RATES BY GENDER (ESTIMATED
RATES PER 100,000 POPULATION) 245
TABLE 150 U.S. LYMPHOMA INCIDENCE RATES BY RACE, 2005-2009 (PER 100,000
POPULATION) 246
TABLE 151 U.S. LYMPHOMA MORTALITY RATES BY RACE, 2005-2009 (PER 100,000
POPULATION) 246
Race and Ethnicity 247
Children 247
Adolescents and Young Adults 247
Adults 248
Survival 248
TABLE 152 STAGE DISTRIBUTION AND FIVE-YEAR RELATIVE SURVIVAL OF ALL
RACES, BOTH SEXES BY STAGE AT DIAGNOSIS, 2002-2008 (%) 249
LYMPHOMA IN THE UNITED KINGDOM 249
TABLE 153 NEW CASES OF NON-HODGKIN LYMPHOMA IN THE U.K., 2013 (NO.) 250
TABLE 154 NON-HODGKIN LYMPHOMA DEATHS IN THE U.K. BY SEX, 2012 (NO.) 253
Hodgkin Lymphoma in the United Kingdom 253
TABLE 155 ESTIMATED NUMBER OF NEW CASES OF HODGKIN LYMPHOMA IN THE
U.K., 2013 (NO.) 254
TABLE 156 ESTIMATED NUMBER OF DEATHS FROM HODGKIN'S LYMPHOMA IN THE
U.K., 2012 (NO.) 255
FIGURE 17 ESTIMATED NUMBER OF DEATHS FROM HODGKIN?S LYMPHOMA IN THE
U.K., 2012 (NO.) 255
MYELOMA 256
SYMPTOMS 256
MYELOMA INCIDENCE WORLDWIDE 256
TABLE 157 ESTIMATED GLOBAL INCIDENCE OF MYELOMA, 2008 (RATES PER
100,000 POPULATION) 257
FIGURE 18 ESTIMATED GLOBAL INCIDENCE OF MYELOMA, 2008 (RATES PER
100,000 POPULATION) 258
TABLE 158 ESTIMATED GLOBAL MYELOMA MORTALITY RATES BY REGION, 2008
(PER 100,000 POPULATION) 259
FIGURE 19 ESTIMATED GLOBAL MYELOMA MORTALITY RATES BY REGION, 2008
(PER 100,000 POPULATION) 260
MYELOMA IN EUROPEAN UNION COUNTRIES 261
TABLE 159 ESTIMATED INCIDENCE OF MYELOMA IN EU-27 COUNTRIES, 2012 (NO.) 261
TABLE 160 DEATHS FROM MYELOMA IN EU-27 COUNTRIES, 2012 (NO.) 263
MYELOMA IN THE UNITED STATES 264
TABLE 161 ESTIMATED MYELOMA INCIDENCE AND DEATHS IN THE U.S., 2011-2016
(NO.) 264
FIGURE 20 ESTIMATED MYELOMA INCIDENCE AND DEATHS IN THE U.S., 2011-2016
(NO.) 265
TABLE 162 ESTIMATED INCIDENCE OF MYELOMA BY GENDER IN THE U.S.,
2011-2016 (NO.) 265
FIGURE 21 ESTIMATED INCIDENCE OF MYELOMA BY GENDER IN THE U.S.,
2011-2016 (NO.) 265
TABLE 163 AGE-ADJUSTED INCIDENCE RATES OF MYELOMA IN THE U.S. BY RACE,
SEER 18 2009-2013 (PER 100,000 POPULATION) 267
TABLE 164 AGE-ADJUSTED DEATH RATES FROM MYELOMA IN THE U.S. BY RACE,
SEER 18 2009-2013 (PER 100,000 POPULATION) 268
Survival 268
TABLE 165 DISTRIBUTION AND FIVE-YEAR RELATIVE SURVIVAL FOR ALL AGES AND
BOTH SEXES IN THE U.S. BY STAGE AT DIAGNOSIS, 2002-2008 (%) 268
MYELOMA IN THE UNITED KINGDOM 269
TABLE 166 NEW CASES OF MYELOMA IN THE U.K., 2013 (NO.) 270
TABLE 167 MYELOMA DEATHS IN THE U.K., 2012 (NO.) 271
CONCLUSIONS 271
MYELODYSPLASTIC SYNDROMES 271
SIGNS AND SYMPTOMS 272
TABLE 168 ESTIMATED NEW CASES OF MDS IN THE U.S., 2012 (NO.) 273
RACE AND ETHNICITY 274
BLOOD DISEASES AND INCIDENCE 274
ANEMIA 275
SICKLE CELL ANEMIA 275
THALASSEMIA 276
BLEEDING DISORDERS 277
HEMOPHILIA 277
Worldwide Incidence of Hemophilia 278
Mortality/Morbidity 278
Hemophilia in the United States 279
CLOTTING DISORDERS 279
CHAPTER 11 HEMATOLOGY INSTRUMENTS AND REAGENTS: A GLOBAL MARKET
PERSPECTIVE 282
HEMATOLOGICAL MALIGNANCIES 282
MARKET DYNAMICS: HEMATOLOGY INSTRUMENTS AND REAGENTS 282
TABLE 169 KEY FACTORS DRIVING THE GROWTH OF THE HEMATOLOGICAL
DISORDERS MARKET 283
TABLE 170 GLOBAL HEMATOLOGY INSTRUMENTS AND REAGENTS MARKET,
THROUGH 2020 ($ MILLIONS) 284
FIGURE 22 GLOBAL HEMATOLOGY INSTRUMENTS AND REAGENTS MARKET,
2012-2020 ($ MILLIONS) 284
GLOBAL MARKET 285
Market Drivers 285
TABLE 171 KEY HEMATOLOGY PRODUCTS 286
Key Players in Hematology Instruments 286
TABLE 172 GLOBAL MAJOR COMPANIES IN THE HEMATOLOGY MARKET 287
Key Company Profiles 287
Roche 287
Sysmex 288
Flow Cytometers 288
TABLE 173 KEY PLAYERS IN FLOW CYTOMETRY 289
TABLE 174 GLOBAL FLOW CYTOMETRY INSTRUMENTS AND REAGENTS MARKET,
THROUGH 2020 ($ MILLIONS) 290
FIGURE 23 GLOBAL FLOW CYTOMETRY INSTRUMENTS AND REAGENTS MARKET,
2012-2020 ($ MILLIONS) 290
TABLE 175 MAJOR FLOW CYTOMETRY APPLICATIONS 291
Coagulation Analyzers 291
TABLE 176 CELL ANALYZERS 292
Future Outlook 293
HEMATOLOGY TEST PRODUCTS AND MARKET 294
TABLE 177 HEMATOLOGY TESTS 294
COMPLETE BLOOD COUNT (CBC) 295
TABLE 178 COMPLETE BLOOD COUNT: COMPONENTS MEASURED 295
MAJOR ROUTINE AND SPECIAL HEMATOLOGY TESTS 296
Partial Thromboplastin Time 296
Total Serum Protein 296
Chemistry Panel 296
TABLE 179 TESTS INCLUDED IN A CHEMISTRY SCREEN 297
TABLE 180 CHEMISTRY SCREEN 297
Vitamin B12 297
The Cold Agglutinins Test 298
Prothrombin 298
Reticulocyte 298
Urine Cytology 298
TABLE 181 URINE TESTS AND APPLICATIONS 299
BLOOD PROTEIN TESTING 299
TUMOR MARKER TESTS 300
IN VITRO DIAGNOSTIC MARKET 300
TABLE 182 GLOBAL IVD PRODUCTS MARKET, THROUGH 2020 ($ MILLIONS) 301
FIGURE 24 GLOBAL IVD PRODUCTS MARKET, 2012-2020 ($ MILLIONS) 301
TABLE 183 U.S. IVD MARKET, THROUGH 2020 ($ MILLIONS) 302
FIGURE 25 U.S. IVD MARKET, 2012-2020 ($ MILLIONS) 302
Immunoassays 303
TABLE 184 GLOBAL MARKET FOR IMMUNOASSAY SYSTEMS, THROUGH 2020 ($
MILLIONS) 303
FIGURE 26 GLOBAL MARKET FOR IMMUNOASSAY SYSTEMS, 2012-2020 ($
MILLIONS) 303
Market Trends 303
TABLE 185 GLOBAL MARKET FOR ENZYME IMMUNOASSAY SYSTEMS, THROUGH
2020 ($ MILLIONS) 304
FIGURE 27 GLOBAL MARKET FOR ENZYME IMMUNOASSAY SYSTEMS, 2015-2020 ($
MILLIONS) 304
TABLE 186 KEY PLAYERS IN THE IMMUNOASSAYS MARKET 305
Molecular Diagnostics 305
TABLE 187 GLOBAL MOLECULAR DIAGNOSTICS MARKET, THROUGH 2020 ($
MILLIONS) 306
FIGURE 28 GLOBAL MOLECULAR DIAGNOSTICS MARKET, 2015-2020 ($ MILLIONS) 306
TABLE 188 MAJOR PLAYERS IN MOLECULAR DIAGNOSTICS MARKET 307
POINT-OF-CARE MARKET 307
TABLE 189 GLOBAL POINT-OF-CARE TESTING MARKET, THROUGH 2020 ($
MILLIONS) 308
FIGURE 29 GLOBAL POINT-OF-CARE TESTING MARKET, 2015-2020 ($ MILLIONS) 308
TABLE 190 POC TESTING KITS 309
POC Tests 309
TABLE 191 GLOBAL MARKET FOR POC TESTS, THROUGH 2020 ($ MILLIONS) 309
FIGURE 30 GLOBAL MARKET FOR POC TESTS, 2015-2020 ($ MILLIONS) 309
POC Immunoassays 310
TABLE 192 GLOBAL POINT-OF-CARE IMMUNOASSAY MARKET, THROUGH 2020 ($
MILLIONS) 311
FIGURE 31 GLOBAL POINT-OF-CARE IMMUNOASSAY MARKET, 2015-2020 ($
MILLIONS) 311
Cardiac Markers 311
TABLE 193 TYPES OF CARDIAC MARKERS 312
POC Market Penetration 312
Future Outlook 312
BLOOD TRANSFUSION DIAGNOSTIC AND BLOOD SCREENING MARKET 313
TABLE 194 KEY MARKET PLAYERS IN THE BLOOD SCREENING MARKET 314
CONCLUSIONS 314
CHAPTER 12 GLOBAL MARKET FOR TREATMENTS FOR HEMATOLOGICAL DISORDERS 316
THERAPEUTIC DRUG MARKET 316
TABLE 195 GLOBAL MARKET FOR TREATMENTS FOR HEMATOLOGICAL DISORDERS,
BY TYPE, THROUGH 2020 ($ MILLIONS) 316
FIGURE 32 GLOBAL MARKET FOR TREATMENTS FOR HEMATOLOGICAL DISORDERS,
BY TYPE, 2012-2020 ($ MILLIONS) 316
TABLE 196 GLOBAL MARKET SHARES OF TREATMENTS FOR HEMATOLOGICAL
DISORDERS BY TYPE, 2015 AND 2020 (%) 317
KEY MARKET PLAYERS 318
TABLE 197 PATENT EXPIRIES OF MAJOR BLOCKBUSTERS DRUGS 318
TABLE 198 GLOBAL KEY PLAYERS OF HEMATOLOGICAL DISORDERS MARKET BY
PRODUCTS AND MARKET SHARE, 2015 (%) 318
TABLE 199 MARKET DRIVERS OF HEMATOLOGICAL DISORDERS 319
TABLE 200 MARKET RESTRAINTS OF HEMATOLOGICAL DISORDERS 319
ANEMIA TREATMENT MARKET 319
TABLE 201 GLOBAL ANEMIA TREATMENT MARKET, THROUGH 2020 ($ MILLIONS) 320
FIGURE 33 GLOBAL ANEMIA TREATMENT MARKET, 2012-2020 ($ MILLIONS) 320
TABLE 202 TYPES OF ANEMIA 320
Anemia Treatments 321
TABLE 203 COMMON ANEMIA TREATMENTS 321
TABLE 204 ERYTHROPOIETIN STIMULATING AGENTS 322
Aranesp 322
TABLE 205 KEY ANEMIA DRUGS SALES, 2012 AND 2015 ($ MILLIONS) 323
FIGURE 34 KEY ANEMIA DRUGS SALES, 2012 AND 2015 ($ MILLIONS) 323
Epogen 324
Procrit 324

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
Hemophilia Treatment Drugs Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2016 - 2024

Hemophilia Treatment Drugs Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2016 - 2024

  • $ 5795
  • Industry report
  • January 2017
  • by Transparency Market Research

Global Hemophilia Treatment Drugs Market: Overview Hemophilia is a rare blood disorder. Hemophilia is a combination of two Greek words that is haima (blood) and philia (affection). Hemophilia is a hereditary ...

Apheresis Market by Product, Procedure, Application, Technology - Global Forecast to 2021

Apheresis Market by Product, Procedure, Application, Technology - Global Forecast to 2021

  • $ 5650
  • Industry report
  • February 2017
  • by MarketsandMarkets

The global apheresis market is projected to reach USD 2.06 billion by 2021, at a CAGR of 7.7% during the forecast period of 2016 to 2021. Growth in this market is majorly driven by the rising prevalence ...

Epiomic Epidemiology Series: Polycythemia Vera Forecast in 27 Major Markets 2016-2026

Epiomic Epidemiology Series: Polycythemia Vera Forecast in 27 Major Markets 2016-2026

  • $ 5112
  • Industry report
  • December 2016
  • by Black Swan Analysis Ltd

Black Swan Analysis Epiomic™ Epidemiology Series Forecast Report on Polycythemia Vera in 27 Major Markets Polycythemia Vera (PV), also known as erythraemia, erythrocytosis, erythrocytosis megalosplenica, ...


Download Unlimited Documents from Trusted Public Sources

Blood Disease and HIV AIDS Statistics in Africa and Malawi

  • March 2017
    22 pages
  • Blood Disease  

    HIV AIDS  

    Infectious Dise...  

  • Africa  

    Malawi  

View report >

Blood Disease Statistics in the US - Forecast

  • March 2017
    10 pages
  • Blood Disease  

    Compression The...  

    Cardiovascular ...  

  • United States  

View report >

Blood Disease Statistics in the US

  • March 2017
    5 pages
  • Blood Disease  

    Pumpkin  

  • United States  

View report >

Related Market Segments :

Blood Disease

ref:plp2016

Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.